Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Front Cardiovasc Med ; 11: 1417074, 2024.
Article in English | MEDLINE | ID: mdl-39139751

ABSTRACT

A 49-year-old female patient, asymptomatic, presented to the cardiology office for a right atrial mass, identified incidentally in a non-electrocardiogram (ECG)-gated contrast-enhanced computed tomography, performed for follow-up of pulmonary tuberculosis. Echocardiography, surprisingly, showed an anechogenic ovoid mass in the right atrium measuring 40 × 40 mm2, implanted in the interatrial septum without affecting the tricuspid valve. ECG-gated computed tomography angiography (CTA), confirmed the dimensions of the mass, which presented homogeneous content, calcified areas, and a 12-mm pedicle implanted near the ostium of the coronary sinus. Additionally, contrast uptake and infiltration of adjacent structures were ruled out. In the surgical field, an encapsulated mass with blood content was found, which pathology reported as a hematic endocardial cyst (HEC). These are rare cardiac masses, constituting 1.5% of all primary cardiac tumors. It is usually an incidental finding, and its clinical presentation will depend on its dimensions and the intracardiac hemodynamic impact. A highlighting feature is its anechogenic content on ultrasound, however, multimodality imaging allows for making diagnostic assumptions, discerning between primary cardiac tumors, and provides morphological and hemodynamic information useful for therapeutic decision making. The age of the patient, the large size of the HEC, and its location in the interatrial septum make up a completely atypical presentation of this rare disease, which motivated this report.

2.
Eur Heart J Imaging Methods Pract ; 2(1): qyae005, 2024 Jan.
Article in English | MEDLINE | ID: mdl-39045196

ABSTRACT

Health problems in the Latin American and the Caribbean (LAC) region are highly concentrated on non-communicable diseases, being cardiovascular diseases (CVDs) and cancer the leading causes of death. Different countries of the region are at different stages of development in addressing CVDs and cancer. Opportunities for training and continuing education in cardio-oncology, as well as active cardio-oncology groups, are primarily limited to large academic institutions in major metropolitan areas. In addition, the development of advanced imaging modalities in LAC faces challenges such as the high cost of equipment, a lack of equipment maintenance and service, as well as insufficient specific training for both imaging specialists and referring clinicians. To contribute to the implementation of actionable strategies ensuring equitable access to care for all, international organizations, such as the International Atomic Energy Agency (IAEA), offer support for the regional development of health projects that address educational needs. In this context, a new IAEA regional cooperation project for LAC titled 'Strengthening of regional capacities on the use of Nuclear Medicine techniques in a Cardio-oncology multimodality approach in patients with cancer' will be developed during 2024-2025. The experience of some centres, as well as national experiences in certain countries of the region, that have been previously involved in other regional projects, can be leveraged for the benefit of the entire region. We present a proposed road map for cross-institutional/countries collaboration in the development of cardio-oncology in the LAC region, contributing to decreasing the barriers to the growth of the subspecialty.

3.
Front Cardiovasc Med ; 10: 1149613, 2023.
Article in English | MEDLINE | ID: mdl-37180790

ABSTRACT

Objectives: The aim of the present study is to assess multimodality imaging findings according to systemic biomarkers, high-sensitivity troponin I (hsTnI) and B-type natriuretic peptide (BNP) levels, in low-flow, low-gradient aortic stenosis (LFLG-AS). Background: Elevated levels of BNP and hsTnI have been related with poor prognosis in patients with LFLG-AS. Methods: Prospective study with LFLG-AS patients that underwent hsTnI, BNP, coronary angiography, cardiac magnetic resonance (CMR) with T1 mapping, echocardiogram and dobutamine stress echocardiogram. Patients were divided into 3 groups according to BNP and hsTnI levels: Group 1 (n = 17) when BNP and hsTnI levels were below median [BNP < 1.98 fold upper reference limit (URL) and hsTnI < 1.8 fold URL]; Group 2 (n = 14) when BNP or hsTnI were higher than median; and Group 3 (n = 18) when both hsTnI and BNP were higher than median. Results: 49 patients included in 3 groups. Clinical characteristics (including risk scores) were similar among groups. Group 3 patients had lower valvuloarterial impedance (P = 0.03) and lower left ventricular ejection fraction (P = 0.02) by echocardiogram. CMR identified a progressive increase of right and left ventricular chamber from Group 1 to Group 3, and worsening of left ventricular ejection fraction (EF) (40 [31-47] vs. 32 [29-41] vs. 26 [19-33]%; p < 0.01) and right ventricular EF (62 [53-69] vs. 51 [35-63] vs. 30 [24-46]%; p < 0.01). Besides, there was a marked increase in myocardial fibrosis assessed by extracellular volume fraction (ECV) (28.4 [24.8-30.7] vs. 28.2 [26.9-34.5] vs. 31.8 [28.9-35.5]%; p = 0.03) and indexed ECV (iECV) (28.7 [21.2-39.1] vs. 28.8 [25.4-39.9] vs. 44.2 [36.4-51.2] ml/m2, respectively; p < 0.01) from Group 1 to Group 3. Conclusions: Higher levels of BNP and hsTnI in LFLG-AS patients are associated with worse multi-modality evidence of cardiac remodeling and fibrosis.

6.
Rev. urug. cardiol ; 32(3): 357-369, dic. 2017. ilus
Article in Spanish | LILACS | ID: biblio-903602

ABSTRACT

En la presente revisión los autores abordan el concepto de multimodalidad de imagen a través del conocimiento de las diferentes técnicas de imagen cardiológica y el aporte de cada una de ellas al diagnóstico de la insuficiencia cardíaca para así construir un esquema de secuencias de estudios o complementariedad de los mismos por separado o en conjunto (técnicas de fusión) aplicable a los pacientes con insuficiencia cardíaca confirmada o sospechada. Se analizan someramente los fundamentos técnicos y clínicos de cada técnica, los aportes de la multimodalidad al diagnóstico de insuficiencia cardíaca encarando las perspectivas futuras de esta metodología. Al final del capítulo se ofrece un resumen conceptual para la aplicación práctica de los conceptos analizados en el mismo.


In this review the authors intend to approach to the concept of multimodality of images, through the knowledge of the different techniques and the contribution of each of them to the diagnosis of heart failure, in order to construct a scheme of studies sequences or complementarity of them, either separately or together (fusion techniques) applicable to the patient with confirmed or suspected heart failure. They briefly analyze the technical and clinical bases of each technique, the contributions of multimodality to the diagnosis of heart failure facing the future perspectives of this methodology. At the end of the chapter a conceptual summary is offered for the practical application of the concepts analyzed above.


Subject(s)
Humans , Multimodal Imaging/standards , Heart Failure , Diagnostic Techniques, Cardiovascular
7.
Rev. urug. cardiol ; 32(3): 359-371, dic. 2017. ilus
Article in Spanish | BVSNACUY | ID: bnu-181821

ABSTRACT

En la presente revisión los autores abordan el concepto de multimodalidad de imagen a través del conocimiento de las diferentes técnicas de imagen cardiológica y el aporte de cada una de ellas al diagnóstico de la insuficiencia cardíaca para así construir un esquema de secuencias de estudios o complementariedad de los mismos por separado o en conjunto (técnicas de fusión) aplicable a los pacientes con insuficiencia cardíaca confirmada o sospechada. Se analizan someramente los fundamentos técnicos y clínicos de cada técnica, los aportes de la multimodalidad al diagnóstico de insuficiencia cardíaca encarando las perspectivas futuras de esta metodología. Al final del capítulo se ofrece un resumen conceptual para la aplicación práctica de los conceptos analizados en el mismo.


Subject(s)
Humans , Heart Failure , Multimodal Imaging/standards , Diagnostic Techniques, Cardiovascular
8.
JACC Cardiovasc Interv ; 9(6): 565-74, 2016 Mar 28.
Article in English | MEDLINE | ID: mdl-27013155

ABSTRACT

OBJECTIVES: This study sought to report the late multimodality imaging and clinical outcomes of the novel poly-l-lactic-acid-based DESolve novolimus-eluting bioresorbable coronary scaffold for the treatment of de novo coronary lesions. BACKGROUND: Bioresorbable scaffolds are an alternative to drug-eluting metallic stents and provide temporary vascular scaffolding, which potentially may allow vessel restoration and reduce the risk of future adverse events. METHODS: Overall, 126 patients were enrolled at 13 international sites between November 2011 and June 2012. The primary endpoint was in-scaffold late lumen loss at 6 months. Major adverse cardiac events, the main safety endpoint, were defined as the composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization. All patients underwent angiography at 6 months. Serial intravascular ultrasound and optical coherence tomography were performed in a subset of patients. RESULTS: The scaffold device success rate was 97% (n = 122 of 126), and procedural success was 100% (n = 122 of 122). The major adverse cardiac event rate was 3.3% (n = 4 of 122) at 6 months and 7.4% (n = 9 of 122) at 24 months, including 1 probable stent thrombosis within the first month. At 6-month angiographic follow-up, in-scaffold late lumen loss was 0.20 ± 0.32 mm. Paired intravascular ultrasound analysis demonstrated a significant increase in vessel, lumen and scaffold dimensions between post-procedure and 6-month follow-up, and strut-level optical coherence tomography analysis showed full strut coverage in 99 ± 1.7%. CONCLUSIONS: Our results showed favorable performance of the DESolve scaffold, effective inhibition of neointimal hyperplasia, and for the first time, early luminal and scaffold growth at 6 months with sustained efficacy and safety through 2 years. (Elixir Medical Clinical Evaluation of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System-The DESolve Nx Trial; NCT02086045).


Subject(s)
Absorbable Implants , Cardiovascular Agents/administration & dosage , Coated Materials, Biocompatible , Coronary Angiography , Coronary Artery Disease/therapy , Coronary Vessels/drug effects , Macrolides/administration & dosage , Percutaneous Coronary Intervention/instrumentation , Tomography, Optical Coherence , Ultrasonography, Interventional , Aged , Brazil , Cardiovascular Agents/adverse effects , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/mortality , Coronary Vessels/diagnostic imaging , Europe , Female , Humans , Hyperplasia , Macrolides/adverse effects , Male , Middle Aged , Neointima , New Zealand , Percutaneous Coronary Intervention/adverse effects , Percutaneous Coronary Intervention/mortality , Predictive Value of Tests , Prospective Studies , Time Factors , Treatment Outcome
9.
Expert Rev Cardiovasc Ther ; 13(6): 715-31, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25912725

ABSTRACT

Nowadays, there is a wide array of imaging studies available for the evaluation of coronary artery disease, each with its particular indications and strengths. Cardiac single photon emission tomography is mostly used to evaluate myocardial perfusion, having experienced recent marked improvements in image acquisition. Cardiac PET has its main utility in perfusion imaging, atherosclerosis and endothelial function evaluation, and viability assessment. Cardiovascular computed tomography has long been used as a reference test for non-invasive evaluation of coronary lesions and anatomic characterization. Cardiovascular magnetic resonance is currently the reference standard for non-invasive ventricular function evaluation and myocardial scarring delineation. These specific strengths have been enhanced with the advent of hybrid equipment, offering a true integration of different imaging modalities into a single, simultaneous and comprehensive study.


Subject(s)
Coronary Artery Disease/diagnosis , Multimodal Imaging/methods , Coronary Artery Disease/physiopathology , Humans , Magnetic Resonance Imaging/methods , Positron-Emission Tomography/methods , Tomography, Emission-Computed, Single-Photon/methods , Tomography, X-Ray Computed/methods
10.
Echocardiography ; 31(10): E296-9, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25087483

ABSTRACT

Lateral left ventricular wall rupture (LVWR) is a rare complication following acute myocardial infarction (AMI) less than 1%. After cardiogenic shock, LVWR constitutes the most common cause of in-hospital death in AMI patients. Around 40% of all LVWR occurred during the first 24 hours and 85% within the first week. In the present case, 76 hours following the intervention, LVWR was observed likely due to a small infarction at the lateral left ventricular wall possibly due to the marginal lesion. Our patient refused surgery and was followed clinically. Eighteen months later, real time three-dimensional echocardiography showed a pseudoaneurysm.


Subject(s)
Aneurysm, False/diagnosis , Heart Rupture, Post-Infarction/diagnosis , Multimodal Imaging/methods , Myocardial Infarction/diagnostic imaging , Aneurysm, False/etiology , Angioplasty, Balloon, Coronary/methods , Coronary Angiography/methods , Coronary Stenosis/diagnostic imaging , Coronary Stenosis/therapy , Echocardiography/methods , Echocardiography, Doppler, Color/methods , Echocardiography, Three-Dimensional/methods , Follow-Up Studies , Heart Rupture, Post-Infarction/complications , Heart Rupture, Post-Infarction/therapy , Heart Ventricles/diagnostic imaging , Heart Ventricles/pathology , Humans , Magnetic Resonance Imaging, Cine/methods , Monitoring, Physiologic/methods , Myocardial Infarction/complications , Myocardial Infarction/therapy , Risk Assessment , Time Factors , Treatment Refusal
SELECTION OF CITATIONS
SEARCH DETAIL